Track Relmada Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Relmada Therapeutics, Inc. RLMD · Stock Open Relmada Therapeutics, Inc. in new tab

4.21 USD
EPS
-0.91
P/B
2.17
ROE
-64.66
Beta
0.57
Target Price
10.75 USD
Loading chart...
Key Metrics
Earnings dateMarch 23, 2027
EPS-0.91
Book Value1.94
Price to Book2.17
Debt/Equity0.10
% Insiders3.602%
Estimates
Forward P/E-10.27
Forward EPS-0.41
Target Mean Price10.75

DCF valuation

Model fair value for Relmada Therapeutics, Inc. (RLMD)
Result
Sign in to run the valuation for RLMD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus Strong buy · mean target 10.75 USD (low 9.00, high 12.00) · as of 14 Nov 2026
Low 9.00
Mean 10.75
High 12.00
Price 4.21
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Relmada Therapeutics, Inc. Logo Relmada Therapeutics, Inc. Analysis (RLMD)

United States Health Care Official Website Stock

Is Relmada Therapeutics, Inc. a good investment? Relmada Therapeutics, Inc. (RLMD) is currently trading at 4.21 USD. Market analysts have a consensus price target of 10.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Relmada Therapeutics, Inc. is expected to release its next earnings report on March 23, 2027. The market consensus estimate for Forward EPS is -0.41.

Investor FAQ

Does Relmada Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Relmada Therapeutics, Inc.?

Relmada Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 23, 2027. The company currently has a trailing EPS of -0.91.

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Exchange Ticker
NMS (United States) RLMD
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 12, 2015 1:5
Sept. 30, 2019 1:4
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion